Conv. Plasma
Nigella Sativa

All sotrovimab studies
Meta analysis
study COVID-19 treatment researchSotrovimabSotrovimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)

Sheward et al., bioRxiv, doi:10.1101/2021.12.19.473354
Dec 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Sotrovimab for COVID-19
39th treatment shown to reduce risk in May 2023
*, now known with p = 0.0017 from 22 studies, recognized in 36 countries. Efficacy is variant dependent.
Lower risk for hospitalization.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
In Vitro study showing that omicron is substantially resistant to neutralization by monoclonal antibodies REGN10933, REGN10987, Ly-CoV016 and Ly-CoV555. S309 (the parent of Sotrovimab) had only 2-fold loss in potency.
Study covers casirivimab/imdevimab, bamlanivimab/etesevimab, and sotrovimab.
Sheward et al., 20 Dec 2021, preprint, 11 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperSotrovimabAll
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
Daniel J Sheward, Changil Kim, Roy A Ehling, Alec Pankow, Xaquin Castro Dopico, Darren Martin, Sai Reddy, Joakim Dillner, Gunilla B Karlsson Hedestam, Jan Albert, Ben Murrell
The recently-emerged SARS-CoV-2 B.1.1.529 variant (Omicron) is spreading rapidly in many countries, with a spike that is highly diverged from the pandemic founder, raising fears that it may evade neutralizing antibody responses. We cloned the Omicron spike from a diagnostic sample which allowed us to rapidly establish an Omicron pseudotyped virus neutralization assay, sharing initial neutralization results only 13 days after the variant was first reported to the WHO, 8 days after receiving the sample. Here we show that Omicron is substantially resistant to neutralization by several monoclonal antibodies that form part of clinical cocktails. Further, we find neutralizing antibody responses in pooled reference sera sampled shortly after infection or vaccination are substantially less potent against Omicron, with neutralizing antibody titers reduced by up to 45 fold compared to those for the pandemic founder. Similarly, in a cohort of convalescent sera prior to vaccination, neutralization of Omicron was low to undetectable. However, in recent samples from two cohorts from Stockholm, Sweden, antibody responses capable of cross-neutralizing Omicron were prevalent. Sera from infected-then-vaccinated healthcare workers exhibited robust cross-neutralization of Omicron, with an average potency reduction of only 5-fold relative to the pandemic founder variant, and some donors showing no loss at all. A similar pattern was observed in randomly sampled recent blood donors, with an average 7-fold loss of potency. Both cohorts showed substantial between-donor heterogeneity in their ability to neutralize Omicron. Together, these data highlight the extensive but incomplete evasion of neutralizing antibody responses by the Omicron variant, and suggest that increasing the magnitude of neutralizing antibody responses by boosting with unmodified vaccines may suffice to raise titers to levels that are protective.
Author Contributions Methods Ethics statement HW and Convalescent cohorts: Informed consent was obtained from all participants as part of an ethics approval (Decision number 2020-01620, with amendments 2020-02881 and 2020-05630) from the Swedish Ethical Review Authority. BD cohort and the Omicron-positive sample from which the spike was cloned were anonymized, and not subject to ethical approvals, as per advisory statement 2020-01807 from the Swedish Ethical Review Authority. Donor sample description Two cohorts were studied. Cohort 1 comprised serum samples with detectable neutralization against the Wu-Hu-1 founder variant from 17 anonymized blood donors ("BD"), donated during week 48, 2021, in Stockholm, Sweden. Cohort 2 comprised 17 serum samples from Hospital Workers ("HW") at the Karolinska University Hospital in Stockholm 20 , who were invited to participate in a study that aimed to characterize their antibody responses following SARS-CoV-2 infection and subsequent vaccinations. Participants, confirmed PCR positive, had serum sampled in April/May 2020, in June/July 2020 ("convalescent", prior to vaccination), and again in November 2021 ("HW"). Convalescent samples are from 9 unique donors, with 3 donors sampled in both April/May 2020 and June/July 2020. Statistical comparison was performed on the 9 samples from June/July 2020 only, to avoid non-independence due to repeated sampling of 3 donors. Supplementary Figure 4 ...
Briefing, SARS-CoV-2 variants of concern and variants under investigation in England
Cele, Jackson, Khan, SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection, doi:10.1101/2021.12.08.21267417
Choi, Koch, Wu, Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis, Nat Med
Corbett, Nason, Flach, Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates, Science
Elfström, Blomqvist, Nilsson, Differences in risk for SARS-CoV-2 infection among healthcare workers, Prev Med Rep
Freed, Silander, SARS-CoV2 genome sequencing protocol (1200bp amplicon 'midnight' primer set, using Nanopore Rapid kit)
Goldberg, Mandel, Bar-On, Waning Immunity after the BNT162b2 Vaccine in Israel, N Engl J Med
Greaney, Loes, Crawford, Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies, Cell Host Microbe
Hansen, Baum, Pascal, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science
Jones, Brown-Augsburger, Corbett, The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates, Sci Transl Med, doi:10.1126/scitranslmed.abf1906
Khoury, Cromer, Reynaldi, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med
Klevebro, Bahram, Elfström, Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care, Scand J Public Health
Kuhlmann, Mayer, Claassen, Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine, doi:10.2139/ssrn.3981711
Levin, Lustig, Cohen, Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months, N Engl J Med
Muecksch, Weisblum, Barnes, Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations, Immunity
Pinto, Park, Beltramello, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature
Seow, Graham, Merrick, Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans, Nat Microbiol
Sheward, Mandolesi, Urgard, Kim, Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models, Cell Rep
Wang, Muecksch, Schaefer-Babajew, Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection, Nature
Weinreich, Sivapalasingam, Norton, REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19, N Engl J Med
Wu, Li, Wang, Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study, Antimicrob Agents Chemother
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop